NEO Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$19.72median target· current $15.29 (+29.0%)12 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—Forward 222.22
EPS (TTM)$-0.39130.6% YoY
Profit margin-6.8%HEALTHCARE
Market cap$1.96BSmall cap
Valuation
- Forward P/E
- 222.22
- PEG ratio
- 2.09
- P/B
- 2.50
- P/S (TTM)
- 2.56
- EV/EBITDA
- 168.03
Profitability & growth
- ROE (TTM)
- -6.3%
- Operating margin
- -4.8%
- Revenue growth YoY
- 11.2%
- Dividend yield
- —
- Beta
- 1.74
Last earnings
Jul 28, 2026 · Estimate $-0.06 · Reported $-0.01
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About NeoGenomics Inc
Company profileNeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company is headquartered in Fort Myers, Florida.
Classification
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 9490 NEOGENOMICS WAY, FORT MYERS, FL
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$1.96B
Shares outstanding$128.5M
52W high$16.17
52W low$5.09
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent